VasoDynamics files global patent (PCT) for NG11-2 platform formulation and production

Platform Intellectual Property protection extended to 2042


5th March 2022
– VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, today announces that it has filed a global Patent Co-Operation Treaty (PCT) for the platform formulation on which topical programmes NG11, NG12 and NG13 are based, and related manufacturing technology, supported by leading IP agency Gill Jennings & Every LLP.

Ningfeng Fiona Li, CEO of VasoDynamics, said:

“The extended intellectual property protection represents an important element of our IP strategy as we progress a number of programmes aimed at transforming the standard of supportive care for a broad range of cancer patients worldwide.”

For enquiries, please contact:

Ningfeng Fiona Li, CEO +44 7969132263
fiona.li@vasodynamics.co.uk
Gary Bower, COO +44 7960388412
gary.bower@vasodynamics.co.uk

Notes to Editors:

About VasoDynamics

VasoDynamics is a UK-based pharmaceutical development company focused on improving the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, VasoDynamics is developing cost-effective medicines for the prevention and treatment of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy-induced mucositis, dermatitis and hair-loss. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculature to achieve the most effective protection of normal tissue during cancer treatment whilst enhancing anti-cancer therapy efficacy.